548 related articles for article (PubMed ID: 33603158)
41. CAR T cells: Building on the CD19 paradigm.
Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
[TBL] [Abstract][Full Text] [Related]
42. Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
Irving M; Lanitis E; Migliorini D; Ivics Z; Guedan S
Hum Gene Ther; 2021 Oct; 32(19-20):1044-1058. PubMed ID: 34662233
[TBL] [Abstract][Full Text] [Related]
43. Chimeric antigen receptor T cell: A cancer immunotherapy.
Singh S; Khasbage S; Kaur RJ; Sidhu JK; Bhandari B
Indian J Pharmacol; 2022; 54(3):226-233. PubMed ID: 35848695
[TBL] [Abstract][Full Text] [Related]
44. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
45. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
46. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
47. T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.
Janelle V; Rulleau C; Del Testa S; Carli C; Delisle JS
Front Immunol; 2020; 11():276. PubMed ID: 32153583
[TBL] [Abstract][Full Text] [Related]
48. Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.
Ghoneim HE; Zamora AE; Thomas PG; Youngblood BA
Trends Mol Med; 2016 Dec; 22(12):1000-1011. PubMed ID: 27825667
[TBL] [Abstract][Full Text] [Related]
49. Current Headway in Cancer Immunotherapy Emphasizing the Practice of Genetically Engineered T Cells to Target Selected Tumor Antigens.
Ray SK; Mukherjee S
Crit Rev Immunol; 2021; 41(1):23-40. PubMed ID: 33822523
[TBL] [Abstract][Full Text] [Related]
50. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
Hammill JA; Afsahi A; Bramson JL; Helsen CW
Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
[TBL] [Abstract][Full Text] [Related]
51. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
52. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
53. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
Front Immunol; 2021; 12():658753. PubMed ID: 33859650
[TBL] [Abstract][Full Text] [Related]
54. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
[TBL] [Abstract][Full Text] [Related]
55. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
Singh H; Huls H; Kebriaei P; Cooper LJ
Immunol Rev; 2014 Jan; 257(1):181-90. PubMed ID: 24329797
[TBL] [Abstract][Full Text] [Related]
56. Industrializing engineered autologous T cells as medicines for solid tumours.
Britten CM; Shalabi A; Hoos A
Nat Rev Drug Discov; 2021 Jun; 20(6):476-488. PubMed ID: 33833444
[TBL] [Abstract][Full Text] [Related]
57. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
[TBL] [Abstract][Full Text] [Related]
58. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
59. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori H; Mansoori Y; Salahi A; Nikfar G; Tavassoli A; Behmard E; Moravej A; Ghasemian A
Mol Biol Rep; 2022 Nov; 49(11):10627-10633. PubMed ID: 35715610
[TBL] [Abstract][Full Text] [Related]
60. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
Curran KJ; Pegram HJ; Brentjens RJ
J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
